Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | RWD from INSIGHT-MM: duration of therapy and treatment sequencing

Guy Pratt • 7 May 2020
Multiple Myeloma

Guy Pratt, MD, FRCP, FRCPath, of University of Birmingham, Birmingham, UK, highlights data coming from a UK-specific analysis of the INSIGHT MM study (NCT02761187). This analysis showed a clear variability in treatment selection and sequencing and treatment discontinuation in UK practice for patients with multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Guy Pratt

1:54
Highlights in myeloma from BSH
Guy Pratt • 4 Apr 2022
1:44
Optimal treatment sequencing in multiple myeloma
Guy Pratt • 4 Apr 2022
1:16
Latest advances in immunotherapy for multiple myeloma: targets, alloCAR-Ts & immunomodulatory drugs
Guy Pratt • 4 Apr 2022
2:17
Cilta-cel: a paradigm shift in the treatment of multiple myeloma
Guy Pratt • 4 Apr 2022

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals